GPT and anemia: In patients treated with encorafenib/cetuximab, all grade ≥3 AEs occurred in <5% of cases, with the more common ones being arthralgia/myalgia (3.9%), abdominal pain (3.6%), anemia (3.6%), nausea/vomiting (3%), and aspartate transaminase (AST)/alanine transaminase (ALT) increase (2.4%).